Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Spring Bank Pharmaceuticals (SBPH) Stock Price
Headlines about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.2536297747562 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Brokerages Expect Spring Bank Pharmaceuticals, Inc. (SBPH) to Announce -$0.46 EPS (americanbankingnews.com)
- Spring Bank Pharmaceuticals: A Run-Up Into Year-End (seekingalpha.com)
- Spring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Spring Bank Pharmaceuticals, Inc. (SBPH) Earns “Buy” Rating from Dawson James (americanbankingnews.com)
- Spring Bank Pharmaceuticals, Inc. (SBPH) Director David Arkowitz Purchases 2,500 Shares (americanbankingnews.com)
Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at 11.99 on Monday. The stock’s market cap is $152.24 million. Spring Bank Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $16.97. The company has a 50 day moving average price of $14.08 and a 200 day moving average price of $11.19.
Several analysts recently weighed in on the company. Dawson James restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Chardan Capital cut their price target on Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, August 1st. Cantor Fitzgerald assumed coverage on Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They issued an “overweight” rating and a $29.00 price target on the stock. Finally, JMP Securities assumed coverage on Spring Bank Pharmaceuticals in a research note on Friday, May 19th. They issued a “market perform” rating and a $20.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.25.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-spring-bank-pharmaceuticals-sbph-stock-price.html.
In other Spring Bank Pharmaceuticals news, Director David Arkowitz acquired 2,500 shares of the stock in a transaction on Friday, August 4th. The shares were bought at an average cost of $12.24 per share, with a total value of $30,600.00. Following the transaction, the director now owns 17,086 shares of the company’s stock, valued at approximately $209,132.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt M. Eichler acquired 76,923 shares of the stock in a transaction on Tuesday, June 27th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $999,999.00. Following the completion of the transaction, the director now directly owns 582,533 shares in the company, valued at approximately $7,572,929. The disclosure for this purchase can be found here. Insiders purchased a total of 81,423 shares of company stock worth $1,055,319 over the last ninety days. Insiders own 17.60% of the company’s stock.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.